Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe to Copromote Moderna’s mRNA Respiratory Vaccines
July 10, 2024
- Mounjaro Winner in May GP Rep Promotion Rankings: Intage
July 9, 2024
- Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
- Shionogi Rolls Out In Vitro Diagnostic for Fetroja in Japan
July 9, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- FunPep to Run Additional Trial for Functional Peptide in Skin Ulcers
July 8, 2024
- Japan Ethical Drug Sales Up 4.9% in May: Crecon
July 8, 2024
- Viatris Begins Japan PIII for IgA Nephropathy Drug
July 5, 2024
- Keytruda Best-Selling Drug in Japan for 9 Months Running: Encise
July 5, 2024
- 32 Pharma Execs Snag 100 Million Yen-Plus in FY2023, Takeda Sweeps Top 3
July 4, 2024
- TMS Gets Rights to Hokkaido University’s Spinal Cord Injury Therapy
July 4, 2024
- Blackstone to Sell Alinamin to MBK Partners
July 4, 2024
- Chugai Grabs Japan’s Best-Paying Pharma Crown Yet Again: Jiho Tally
July 3, 2024
- Mochida Files EPA Agent Epadel in China
July 3, 2024
- China Approves Xtandi for Metastatic Hormone-Sensitive Prostate Cancer: Astellas
July 3, 2024
- Janssen Rebranded as J&J in Japan as Part of Global Move
July 2, 2024
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
- MSD to Transfer Belsomra Distribution Rights to Daiichi Sankyo in Japan
July 2, 2024
- MSD Files Keytruda for Malignant Pleural Mesothelioma in Japan
July 2, 2024
- Eisai to Go Solo on Its 1st ADC after BMS Exits Deal
July 2, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…